ReviewEuropean cardiology2018
Erectile Dysfunction and Ischaemic Heart Disease.
Review in European cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Mean platelet volume as a predictive marker of erectile dysfunction: a meta-analysis.International journal of impotence research · 2022Pooled it
- Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses.BJU international · 2021Pooled it
- Preserving Neurovascular Bundles Preserves the Mind: Cognitive, Functional, and Quality-of-Life Outcomes of Nerve-Sparing Radical Prostatectomy.Research and reports in urology · 2026Article
- Prevalence of Erectile Dysfunction and its Psychological Impact on Patients with Ischaemic Heart Disease in Oman.Sultan Qaboos University medical journal · 2025Article
- Association of Sexual Health and Mental Health in Erectile Dysfunction: Expert Opinion From the Indian Context.Cureus · 2025Review
- 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II.Acta Cardiologica Sinica · 2024Article
- Oxidative Stress and Erectile Dysfunction: Pathophysiology, Impacts, and Potential Treatments.Current issues in molecular biology · 2024Review
- Circulating miRNA-21 is an innovative biomarker for cardiovascular events in erectile dysfunction patients.Frontiers in cardiovascular medicine · 2024Article
- Sex-Related Differences in the Prevalence of Classical, Non-Classical Risk Factors and Management of the Chronic Coronary Syndrome.Journal of clinical medicine · 2023Article
- Relationship Between Age, Comorbidity, and the Prevalence of Erectile Dysfunction.European urology focus · 2023Article
- Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.Diabetologia · 2022Article
- Efficacy of the Orally Disintegrating Strip Sildenafil for the Treatment of Erectile Dysfunction: A Prospective, Randomized Trial.Sexual medicine · 2021Article
- Advances in Nanoparticle Delivery System for Erectile Dysfunction: An Updated Review.Sexual medicine · 2021Article
- Erectile dysfunction and coronary artery calcification in incident dialysis patients.Journal of nephrology · 2021Article
- Sexual Dysfunction and the Impact of Beta-Blockers in Young Males With Coronary Artery Disease.Frontiers in cardiovascular medicine · 2021Article
- A focused review on the genital and sexual affection of COVID-19 patients.Journal of gynecology obstetrics and human reproduction · 2020Article
- Mean Platelet Volume as a Marker of Vasculogenic Erectile Dysfunction and Future Cardiovascular Risk.Journal of clinical medicine · 2020Review
- Modulation of NLRP3 Inflammasome Activation by QYHT Decoction: Implications for the Treatment of Erectile Dysfunction in Hyperuricemia.American journal of men's healthArticle
- Effect of tadalafil combined with atorvastatin on hemodynamics and sexual function in middle-aged and elderly patients with hyperlipidemia complicated with erectile dysfunction.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED) is a common disorder that affects the quality of life of many patients. It is prevalent in more than half of males aged over 60 years. Increasing evidence suggests that ED is predominantly a vascular disorder. Endothelial dysfunction seems to be the common pathological process causing ED. Many common risk factors for atherosclerosis such as diabetes, hypertension, smoking, obesity and hyperlipidaemia are prevalent in patients with ED and so management of these common cardiovascular risk factors can potentially prevent ED. Phosphodiesterase type 5 inhibitors provide short-term change of haemodynamic factors to help initiate and maintain penile erection. They have been shown to be an effective and safe treatment strategy for ED in patients with heart disease, including those with ischaemic heart disease and hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.